8-K: Zentalis Pharmaceuticals Announces Positive Clinical Data for Azenosertib in Ovarian Cancer Treatment

Zentalis Pharmaceuticals presents updated clinical data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer, highlighting azenosertib's potential in treating platinum-resistant ovarian cancer.

Summary

• Zentalis Pharmaceuticals presented updated clinical data from the DENALI Part 1b trial at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting.
• The trial evaluated azenosertib monotherapy in patients with platinum-resistant ovarian cancer (PROC).
• As of January 13, 2025, patients with Cyclin E1+ PROC tumors who were response-evaluable demonstrated an objective response rate (ORR) of 34.9% (15/43).
• In intent-to-treat patients with Cyclin E1+ PROC, the ORR was 31.3% (15/48), with a median duration of response (mDOR) of 6.3 months.
• Cyclin E1 protein overexpression is identified as a predictive biomarker for azenosertib benefit.
• Zentalis estimates that about half of PROC patients overexpress Cyclin E1.
• The safety and tolerability profile was consistent with previous data, with gastrointestinal toxicities and fatigue being the most common adverse events.
• The company is on track to initiate enrollment of DENALI Part 2 in the first half of 2025 and expects topline data by year end 2026.
• Preclinical data also shows synergistic effects of azenosertib with microtubule inhibitor-based antibody drug conjugates (ADCs).

Sentiment

Score: 8

Explanation: The document presents positive clinical data for azenosertib, highlighting its potential as a targeted therapy for platinum-resistant ovarian cancer. The identification of a predictive biomarker and the progress in clinical trials contribute to a positive outlook.

Positives

• Azenosertib demonstrates promising anti-tumor activity in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC).
• Cyclin E1 overexpression is identified as a predictive biomarker, potentially allowing for targeted treatment.
• The safety profile of azenosertib remains consistent with previous data, with manageable adverse events.
• The company is progressing with the DENALI clinical trial, with Part 2 initiation expected in the first half of 2025.
• Preclinical data suggests potential for azenosertib in combination therapies with ADCs.

Negatives

• Gastrointestinal toxicities and fatigue are common treatment-related adverse events associated with azenosertib.
• Hematological toxicities require close monitoring during treatment with azenosertib.
• 21.6% of patients required discontinuation of treatment due to treatment-related adverse events.

Risks

• The median duration of response (mDOR) is subject to change as there were patients with ongoing responses at the data cutoff.
• The success of DENALI Part 2 is necessary for potential accelerated approval, subject to FDA review.
• The Phase 3 randomized confirmatory study is subject to FDA review.
• Clinical trials are subject to unforeseen events that could cause delays or adverse consequences.
• Regulatory approval is not guaranteed.

Future Outlook

Zentalis plans to initiate enrollment of DENALI Part 2 in the first half of 2025 and expects to disclose topline data from DENALI Part 2 by year end 2026. DENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review. Zentalis plans to treat the same patient population in a Phase 3 randomized confirmatory study, subject to FDA review, which the Company plans to enroll concurrently with DENALI Part 2b.

Management Comments

• Ingmar Bruns, M.D., Chief Medical Officer of Zentalis, stated that the presentation of the updated DENALI Part 1b data at the SGO Annual Meeting supports the continued development of azenosertib.
• Ingmar Bruns, M.D., Chief Medical Officer of Zentalis, stated that the clear anti-tumor activity and durable response observed highlights the potential of azenosertib to become an important treatment option for patients with Cyclin E1+ PROC.
• Fiona Simpkins, M.D., Director of Clinical & Translational Gynecologic Oncology Research at the University of Pennsylvania, stated that developing new therapies for this subset of ovarian cancer patients is urgently needed.
• Fiona Simpkins, M.D., Director of Clinical & Translational Gynecologic Oncology Research at the University of Pennsylvania, stated that DENALI Part 1b results are exciting as they show that the WEE1 inhibitor, azenosertib, is active in a Cyclin E1 biomarker selective population potentially addressing a clinical unmet need.

Industry Context

The announcement highlights the ongoing efforts to develop targeted therapies for platinum-resistant ovarian cancer, a challenging disease with limited treatment options. The identification of Cyclin E1 as a predictive biomarker aligns with the industry trend towards personalized medicine and biomarker-driven drug development. The combination of azenosertib with ADCs reflects the growing interest in combination therapies to improve treatment outcomes in advanced solid tumors.

Comparison to Industry Standards

• The objective response rate (ORR) of approximately 35% in Cyclin E1+ PROC patients is a promising result compared to historical response rates with standard chemotherapy in this patient population, which are typically in the range of 10-20%.
• Other WEE1 inhibitors in development, such as adavosertib (AZD1775) by AstraZeneca, have also shown activity in ovarian cancer, but the biomarker-driven approach with Cyclin E1+ selection could potentially differentiate azenosertib.
• The median duration of response (mDOR) of 6.3 months is competitive with other targeted therapies in PROC, but longer follow-up is needed to assess the durability of the response.
• The combination strategy with ADCs is similar to other approaches being explored in the industry, such as combining PARP inhibitors with ADCs in ovarian cancer.

Stakeholder Impact

• Positive clinical data may increase shareholder value.
• Patients with platinum-resistant ovarian cancer may benefit from a new treatment option.
• Employees of Zentalis Pharmaceuticals may experience increased job security and opportunities.
• Positive results may attract potential partners and investors.

Next Steps

• Initiate enrollment of DENALI Part 2 in the first half of 2025.
• Disclose topline data from DENALI Part 2 by year end 2026.
• Enroll a Phase 3 randomized confirmatory study concurrently with DENALI Part 2b, subject to FDA review.
• Present preclinical data of azenosertib during a poster presentation at the SGO Annual Meeting.

Key Dates